Recent News

BriaCell Launches Its Scientific Advisory Board

Berkeley, CA and Vancouver, BC – May 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of immune-oncology. Briacell is an immuno-oncology focused biotechnology company with a proprietary vaccine, Briavax™, […]

Recent News

BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – May 8, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell’s Phase I/IIa clinical trial evaluating the Company’s lead product candidate, BriaVax™, a genetically engineered whole-cell vaccine derived from a human […]